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Abstract
BACKGROUND: In Egypt, schistosomal infestation is a leading cause of bladder cancer. A mutation in the fibroblast 
growth factor receptor 3 (FGFR-3) gene is the most common and most specific genetic abnormality in bladder cancer. 
Similarly, cyclooxygenase-2 (COX-2) is an inducible, pro-inflammatory enzyme with previous studies showing higher 
expression in schistosomal-associated bladder cancer.
AIM OF THE STUDY: The aim of the study was to evaluate the immunohistochemical expression of FGFR3 and 
COX2 in bladder carcinoma and correlates their expression to the associated schistosomal infestation to implicate 
possible therapeutic treatments.
MATERIALS AND METHODS: This retrospective study included a total of 90 cases of archived, formalin fixed, paraffin-
embedded tissue blocks that included variable subtypes and grades of urothelial carcinomas. Immunohistochemistry 
for expression of FGFR-3 and COX2 was performed using a standard avidin-biotin-peroxidase system.
RESULTS: About 73.3% of the total cases (66 cases) showed variable positive reactivity for FGFR3, of which 
33.3% (22 cases) were associated with bilharzia infection. A statistically significant correlation was detected between 
FGFR-3 and tumor size, grade, histologic subtype, LN status, lymphovascular invasion, and stage. About 83.3% of 
the total cases (75 cases) showed variable positive immunoreactivity for COX-2, of which 37.3% (28 cases) were 
bilharzial-associated. A positive correlation was established between COX-2 and grade, concomitant in situ changes 
and cases associated with bilharzia infection.
CONCLUSION: FGFR-3 can be used as a prognostic marker for low-grade urothelial tumors. Results also portray 
that COX-2 has an inflammatory inciting role in bladder carcinoma development, especially in patients with a history of 
schistosomiasis (bilharziasis). Both COX-2 and FGFR-3 should be explored further for its use alone or in combination 
with conventional treatment, to reduce the recurrence rate and progression of superficial (low grade) tumors.
Introduction
Bladder cancer is the sixth most common 
cancer throughout the world [1]. It is the most common 
malignancy among Egyptian males. Schistosomal 
infection is considered a major risk factor for developing 
squamous cell carcinoma (SCC) [32].
At present, there are no validated prognostic 
molecular biomarkers such as T-cell receptor clonality 
and tissue or blood-based immune-gene profiling 
to guide the clinical management of urinary bladder 
cancer. Crucial therapeutic decisions are based on risk 
tables that include tumor size and number, previous 
history, in addition to histopathological criteria which 
are often limited by observer variability and have 
relatively low reproducibility [2]. Factors that include 
choice of antibody, fixation technique, and selection 
of tumor areas to measure staining methods, signal 
detection methods, criteria for positive staining, data 
interpretation guidelines, and stratification criteria 
are all major challenges for the clinical application 
of tissue-based biomarkers in urothelial bladder 
management [27].
Overall, urothelial cancer (UC) management 
would greatly benefit from cost-effective methods 
for screening and surveillance to predict the risks of 
recurrence and progression so that more targeted 
therapeutic regimes and intensive monitoring could be 
focused on patients at higher risk [2], [16], [17].
Fibroblast growth factor receptor 3 (FGFR3) 
has been revealed to possess an oncogenic role in 
numerous types of cancer, especially bladder [3]. 
Patients with FGFR3 alterations tend to have a low 
likelihood of response to chemotherapy or immune 
checkpoint [27]. FGFR3 mutations are found in a large 
proportion of low grade, low stage bladder cancers, the 
development of a robust test detecting these mutations 
would be the most obvious step. It would be a useful 
molecular marker in bladder cancer diagnosis and 
prognosis and could – in theory – provide an excellent 
urine marker for follow-up of patients with low grade 
and low stage bladder cancer [4], [5]. It could also 
guide the management lines in treatment-resistant 
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patients to shift into FGFR inhibitors, e.g., erdafitinib 
and BGJ398 [28].
Cyclooxygenase-2 (COX-2) is an induced 
inflammatory mediator involved in the development of 
tumors responsible for the conversion of arachidonic 
acid to prostaglandins. Overexpression of COX-2 
may play a role in carcinogenesis through cellular 
proliferation, angiogenesis, apoptosis, invasion/motility, 
and immune responses [18]. It is not detectable in 
most normal tissues; however, it is induced at sites 
of inflammation by cytokines, growth factors, and 
tumor promoters that result in upregulation of PD-L1, 
which increase the myeloid-derived suppressor cells 
in peripheral blood and eliminating CD8 T cells from 
urinary bladder cancer [27].
Schistosomiasis has been linked to induce 
urinary bladder cancer by increasing the proliferation of 
urothelium and decreasing apoptosis. The concurrent 
inflammation and presence of possibly mutagenic 
parasite molecules could explain the observation of 
increased chromosomal damage. In addition, there 
is an increase cell proliferation in endothelial cells, 
resulting in angiogenesis with egg granuloma formation. 
The resulting keratinous squamous metaplasia has 
been associated with the increased risk of developing 
squamous cell carcinoma, with approximately one-half 
of the cases arising subsequent to the metaplasia [29].
This study aimed at the assessment of 
immunohistochemical expression of FGFR3 and 
COX-2 in urinary bladder carcinoma in Egyptian 
patients, to investigate their potential role in urothelial 
carcinogenesis. Further assessment is targeted to 
Figure 1: Variable staining degrees of expressing fibroblast growth 
factor receptor 3. (a) Negative staining of low-grade squamous cell 
carcinoma (×200), (b) weak cytoplasmic and membranous staining of 
squamous cell carcinoma (×200), (c) moderate cytoplasmic staining 
of papillary transitional cell carcinoma (TCC) (×200), (d) strong 
membranous and cytoplasmic staining of invasive TCC (×400)
AQ6
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Figure 2: Variable staining degrees of expressing cyclooxygenase-2. 
(a) Negative staining of papillary transitional cell carcinoma (TCC) 
(×200), (b) weak cytoplasmic staining of low-grade squamous cell 
carcinoma (×200), (c) moderate membranous and cytoplasmic 
staining of papillary TCC (×200), (d) strong membranous and 
cytoplasmic staining of squamous cell carcinoma (×200)
AQ6
a b
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Figure 3: Non-invasive papillary transitional cell carcinoma, low-grade, 
(×200) original magnification, hematoxylin and eosin stain. (a) Strong 
membranous fibroblast growth factor receptor 3 immunostaining, 
(b) strong membranous cyclooxygenase-2 immunostaining
AQ6
a b
Figure 4: Invasive papillary transitional cell carcinoma, high grade, 
(×200) original magnification, hematoxylin and eosin stain. (a) 
Strong membranous and cytoplasmic fibroblast growth factor 
receptor 3 immunostaining, (b) Strong membranous and cytoplasmic 
cyclooxygenase-2 immunostaining
AQ6
a b
Figure 5: Squamous cell carcinoma, high grade, with evident 
lymphovascular emboli (×200) original magnification, hematoxylin 
and eosin stain. (a) Strong membranous and cytoplasmic fibroblast 
growth factor receptor 3 immunostaining, (b) strong membranous 
and cytoplasmic cyclooxygenase-2 immunostaining
AQ6
a b
Figure 6: Small cell carcinoma, high grade, (×200 original 
magnification), hematoxylin and eosin stain. (a) Negative fibroblast 
growth factor receptor 3 immunostaining, (b) strong membranous 
and cytoplasmic cyclooxygenase-2 immunostaining
AQ6
a b
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Figure 7: Sarcomatoid carcinoma with diffuse spindling, high grade, 
(×200 original magnification), hematoxylin and eosin stain. (a) Strong 
membranous and cytoplasmic fibroblast growth factor receptor 3 
immunostaining, (b) Negative cyclooxygenase-2 immunostaining
AQ6
a b
the association of their expression to the presence 
of bilharzia infection of these cases with the possible 
role of both FGFR3 and COX-2 as possible usage of 
therapies targeting such receptors.
Figure 8: Transitional cell carcinoma with focal adenoid 
differentiation, high grade, (×200) original magnification, hematoxylin 
and eosin stain. (a) Strong membranous and cytoplasmic fibroblast 
growth factor receptor 3 immunostaining, (b) Strong membranous 
and cytoplasmic cyclooxygenase-2 immunostaining
AQ6
a b
Materials and Methods
This retrospective study was carried out on 
90 cases of randomly chosen formalin-fixed paraffin-
embedded tissue blocks of patients diagnosed 
with bladder carcinoma with or without coexistent 
schistosomal infestation from the archives of our 
pathology department from the period of September 
2017 to July 2018. Patients were operated by 
radical cystectomy or transurethral resection biopsy. 
Clinicopathological data of all cases were recorded from 
the patient records and tabulated. Ethical clearance 
was obtained by the institutional review board prior to 
the study.
Each paraffin block was by cut by rotator 
microtome at 5 μ thickness then mounted on glass 
slides to be stained by hematoxylin and eosin (H&E) for 
histopathological re-evaluation by two pathologists and 
on charged glass slides for immunostaining process. 
The slides deparaffinized and hydrated in xylene. 
Then, they were treated for antigen retrieval (using 
a microwave oven for 30 min) an automated Omnis 
DAKO immunostainer at a high pH of 8.
After this, the sections were treated with antibodies 
using avidin-biotin-peroxidase 3% (Thermo Scientific) for 
30 min. Diaminobenzidine tetrahydrochloride was used 
as a substrate and chromogen. Hematoxylin (Biogenex) 
was used as a counterstain. The primary antibody was 
a mouse monoclonal antibody of anti-FGFR3 which was 
manufactured by Santa Cruz Biotechnology, Inc. (Dallas, 
TX, clone B-9, SC-13121) and used at a dilution of 1:50.
Tumor tissue sections were examined and 
scored under Leica DM500 microscope at low power than 
high power magnification by two independent pathologists 
who were not informed of the histological diagnosis.
Assessment of FGFR3 expression in the tumor 
cells was designated as brownish cytoplasmic and/or 
membranous staining in more than 10% of tumor cells 
(threshold point of positivity). A minimum of 500 cells 
was counted. A case of normal skin was also sectioned 
and underwent the same procedure for each run 
performed to serve as a positive control case. FGFR3 
positivity in the background stroma and in the muscle 
fibers served as a positive internal control.
The same steps were performed for COX-2 
staining but antigen retrieval was done at a lower 
pH (pH 6) and a case of the normal colon was also 
sectioned and underwent the same procedure for each 
run to serve as a positive control. The primary antibody 
was a mouse monoclonal antibody against COX2 
which was manufactured by Santa Cruz Biotechnology, 
Inc. (Dallas, TX, clone H-3, (sc-376861) and used at 
a dilution of 1:100. Assessment of COX-2 expression 
in the tumor cells was designated as brownish 
cytoplasmic and/or membranous staining in more 
than 10% of tumor cells (threshold point of positivity). 
A minimum of 500 cells was counted. COX-2 positivity 
in the background stroma, endothelial cells, and muscle 
fibers served as a positive internal control.
The data were tabulated and Chi-square test 
was used to examine the relation between qualitative 
variables. p < 0.05 was considered significant.
All slides were screened on Leica DM500 
microscope and all photos were imaged by HD 
digital microscope camera, named Leica ICC50 HD, 
connected to the same microscope.
Results
This study included 90 cases of urinary bladder 
cancer, in which the ages of the patients ranged from 41 
to 79 years with a mean age of 64 years. As regards to 
the gender, 73 of the 90 cases were found to be males 
(representing 81.1% of the study) and the remaining 
were females (17 cases; 18.9%). FGFR3 expression 
was established in 66 cases (73.3% of the total cases). 
As for COX2, it was expressed in 75 cases (83.3% of 
total cases). Only one-third of cases (35.5%) showed 
schistosomal affection.
The majority of the cases were found to be 
of high grade (54 cases; 60%) and 36 cases were of 
low grade (representing 40% of the study). A large 
percentage of the low-grade tumors showed positive 
expression for FGFR3 (p = 0.028; 69.4% of the group). 
A similar pattern was also noted among the low-grade 
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tumors showing a positive COX2 expression (p = 0.020; 
83.3% of the group). Further findings also showed 
a positive statistical correlation of positive nodal 
metastasis (p = 0.0006) and positive lymphovascular 
invasion (LVI) (p = 0.0028) in relation to FGFR3; 
however, these results were only seen in regards to LVI 
to COX2 expression.
As regards to tumor size in this study, FGFR3 
demonstrated a positive correlation (p = 0.028) unlike 
COX2 which did not. The bladder carcinoma cases with 
adjacent carcinoma in situ (CIS) were seen in 34.4% 
of this study group and showed a strong relation with 
COX2 (p = 0.034) but showed an insignificant finding in 
correlation to FGFR3 (p = 0.068).
The relationship between FGFR3 and COX2 
expression and the clinicopathological variables 
are shown in Tables 1 and 2, respectively. The 
main histological subtypes included 31 cases of the 
conventional urothelial cell carcinoma constituting 
(34.4%), 22 cases of squamous cell carcinoma 
(25.6%), and urothelial cell carcinoma with squamous 
cell differentiation (13.3%). The remaining cases 
included micropapillary (4 cases), small cell (4 cases), 
sarcomatoid (4 cases), and urothelial cell carcinoma 
Table 1: Clinicopathological characteristics of the studied cases of bladder carcinoma and its correlation with FGFR3 expression
Parameters n (%) Positive FGFR3 expression Negative FGFR3 expression p value
(n=90, 100%) % (n=66, 73.3%) % (n=24, 26.7%) %
Age
≤60 years 43 47.77 30 45.45 13 54.2 0.195
>60 years 47 52.22 36 54.54 11 45.8
Gender
Male 73 81.11 56 84.88 17 70.83 0.191
Female 17 18.88 10 15.12 7 29.17
Tumor size
<3 cm 30 33.33 23 34.88 7 29.17 0.028
3–5 cm 31 34.44 25 37.89 6 25
>5 cm 29 32.22 18 27.23 11 45.83
Grade
Low grade 36 40 25 37.89 11 45.83 0.028
High grade 54 60 41 62.11 13 54.17
Presence of nodal metastasis
Positive 25 27.77 20 30.33 5 20.83 0.0006
Negative 65 72.22 46 69.67 19 79.17
Muscle invasion
Present 79 87.78 57 86.34 22 91.67 0.064
Absent 11 12.22 9 13.66 2 8.33
Lymphovascular invasion
Present 54 60 25 37.89 11 45.83 0.0028
Absent 36 40 41 62.11 13 54.17
Perineural invasion
Present 46 51.11 24 36.34 12 50 0.088
Absent 44 48.89 42 63.66 12 50
Carcinoma in situ
Present 31 34.44 43 65.12 16 66.67 0.068
Absent 59 65.56 23 34.88 8 33.33
Coexisting bilharzial infestation
Present 32 35.56 22 33.33 10 41.67 0.015
Absent 58 64.44 44 66.67 14 58.33
FGFR3: Fibroblast growth factor receptor 3.
Table 2: Clinicopathological characteristics of the studied cases of bladder carcinoma and its correlation with COX-2 expression
Parameters n (%) Positive COX2 expression Negative COX2 expression p value
(n=90, 100%) % (n=75, 83.3%) % (n=15, 16.7%) %
Age
≤60 years 43 47.77 34 45.33 9 60 0.041
>60 years 47 52.22 41 54.66 6 40
Gender
Male 73 81.11 63 84 10 66.67 0.187
Female 17 18.88 12 16 5 33.33
Tumor size
<3 cm 30 33.33 26 34.67 4 26.66 0.069
3–5 cm 31 34.44 24 32 7 46.66
>5 cm 29 32.22 25 33.33 4 26.66
Grade
Low grade 36 40 30 40 6 40 0.020
High grade 54 60 45 60 9 60
Presence of nodal metastasis
Positive 25 27.78 19 25.33 6 40 0.074
Negative 65 72.22 52 69.33 13 86.66
Muscle invasion
Present 79 87.77 55 73.33 14 93.33 0.106
Absent 11 12.22 10 13.33 1 6.66
Lymphovascular invasion
Present 36 40 29 38.66 7 46.66 0.018
Absent 54 60 46 61.33 8 53.33
Perineural invasion
Present 44 48.88 36 48 8 53.33 0.12
Absent 46 51.11 39 52 7 46.67
Carcinoma in situ
Present 31 34.44 25 33.33 6 40 0.034
Absent 59 65.55 50 66.66 9 60
Coexisting bilharzial infestation
Present 32 35.55 28 37.33 4 26.67 0.00
Absent 58 64.44 47 62.66 11 73.33 7
COX-2: Cyclooxygenase-2.
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with focal adenoid differentiation (2 cases). There is no 
significant correlation between expression of FGFR-3 
and COX2 in bladder cancer and histological subtypes 
in this study group as seen in Table 3.
This study also focused on the schistosomal 
(bilharzial) association in Egyptian patients. One-third of 
the cases (35.5%) showed concomitant affection of this 
helminth. Table 4 illustrates the further analysis performed 
on the common significant parameters seen in both FGFR3 
and COX2 positive cases associated with schistosomiasis. 
COX2-associated bilharzial cases demonstrated a positive 
correlation to CIS (p = 0.009). Both FGFR3 and COX2 both 
showed a positive correlation (p = 0.025) and (p = 0.028), 
respectively, in regards to low-grade tumors with bilharzial 
affection in this study. On the other hand, schistosomal 
affected cases did not display significant findings in 
relation to the high-grade tumors that showed FGFR3 and 
COX2 expression. Likewise, no significant findings were 
established in regards to size or LVI.
Discussion
Contrary to the leading etiology of smoking and 
occupational exposures in Western countries, chronic 
bladder infection with Schistosoma haematobium has 
been the most important risk factor for bladder cancer 
in Egypt [8].
The purpose of this study is to determine 
any correlation between primary bladder cancers and 
FGFR-3 and COX-2 protein expression. Furthermore, 
if there is a possible connection between bilharzial-
association in these tumors and these two markers 
as the assessment of combined biomarkers instead of 
a single one will potentially provide a more accurate 
reflection of the underlying biological complexity of 
the antitumor immune response. This present study 
included 90 cases of urothelial bladder carcinomas 
in Egyptian patients. The ages of the patients ranged 
from 41 to 79 with a mean age of 64. These results 
were close to the results recorded by Arsalan et al. [7] 
which displayed a mean age of 62.1 years with 89.1% 
of the cases diagnosed at more than 40 years of age. 
Regarding the gender of the cases in this study, the 
majority were males (81%), similar to Gust et al. [9], in 
which 77% were males.
As for immunostaining for FGFR-3 expression, 
the current study showed that only 24 cases showed 
negative staining and the remaining 66 cases (73.3% 
of total cases) showed positive cytoplasmic and/or 
membranous. Hammam et al. [11] also found that 72% 
of malignant cases in their study were also positive 
for FGFR3 immunostaining, which is compatible 
with another study [10] that stated that expression of 
FGFR3 was found in approximately 70% of both low 
and high-grade tumors, as well as equally distributed 
between invasive and non-invasive urothelial 
carcinoma. Evaluation of the results of immunostaining 
Table 4: Schistosomal-associated cases with positive FGFR3 and COX2 expression and their correlation to similar tumor 
parameters
Schistosomal-associated cases n (%) Positive FGR3 expression p value Positive COX2 expression p value
(n=32, 35.5%) % (n=22, 33.3%) % 0.015 (n=28, 37.3%) % 0.007
Tumor size
<3 cm 10 31.25 8 36.3 10 35.7 0.154
3–5 cm 14 43.75 7 31.8 0.075 12 42.8
>5 cm 8 25 7 31.8 6 21.4
Grade
Low grade 19 59.3 14 63.3 0.025 17 60.7 0.028
High grade 13 40.6 8 36.3 0.109 11 39.3 0.097
Lymphovascular invasion
Present 17 53.1 10 45.4 0.173 15 53.5 0.088
Absent 15 46.8 12 54.5 13 46.4
Carcinoma in situ
Present 14 43.7 9 40.9 0.094 13 46.4 0.009
Absent 18 56.2 13 59.1 15 53.6
FGFR3: Fibroblast growth factor receptor 3, COX2: Cyclooxygenase-2.
Table 3: Histological subtypes and staging of the studied cases and correlation with FGFR3 and COX2 expression
Parameters n (%) Positive FGFR3 
expression 
Negative FGFR3 
expression
p value Positive COX2 
expression 
Negative COX2 
expression
p value
(n=90, 100%) % (n=66, 73.3%) % (n=24, 26.7) % (n=75, 83.3%) % (n=15, 16.7%) %
Histological subtype
Urothelial carcinoma 31 34.44 22 33.33 9 37.5 0.121 24 32 7 46.66 0.144
Urothelial w/squamous cell differentiation 12 13.33 10 15.15 2 8.33 11 14.66 1 6.66
Squamous cell carcinoma 23 25.55 17 25.75 6 25 17 22.66 6 40
Micropapillary 4 4.444 4 6.06 0 0 4 5.33 0 0
Small cell 4 4.444 2 3.03 2 8.33 2 2.66 2 13.33
Sarcomatoid 4 4.444 0 0 4 16.66 0 0 4 26.66
Non-invasive TCC* 10 11.11 10 15.15 0 0 10 13.33 0 0
TCC w/ focal adenoid differentiation 2 2.22 1 1.515 1 4.16 1 1.33 1 6.66
Stage
Ta/T1 19 21.11 16 24.24 3 12.5 0.031 17 22.66 2 13.33 0.1
T2a 7 7.77 6 9.09 1 4.16 4 5.33 3 20 09
T2b 7 7.77 5 7.57 2 8.33 5 6.67 2 13.33
T3a 14 15.55 8 12.12 6 25 10 1.33 4 26.67
T3b 30 33.33 21 31.81 9 37.5 20 26.67 10 66.67
T4a 12 13.33 10 15.15 2 8.33 4 5.33 3 20
T4b 1 1.11 0 0 1 4.166 1 1.33 0 0
*TCC: Transitional cell carcinoma, FGFR3: Fibroblast growth factor receptor 3, COX2: Cyclooxygenase-2.
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for COX-2 showed that only 15 cases were negative 
with the remaining 75 cases (83.3% of total cases) 
showed positive cytoplasmic and/or membranous 
reactivity. Similar findings were reported in another 
study, in which 71.6% of the cases showed COX2 
immunoreactivity [30].
When analyzing the tumor grade in this study, 
close results were similarly reported by Maeng et al. [13], 
in which the majority (81.3%) of the lower-grade 
tumors (PUNLMP and low-grade UC) demonstrated 
cytoplasmic positivity for FGFR-3, whereas only 47.8% 
of high-grade urothelial carcinomas did p = 0.022. In 
a study by Tomlinson et al. [14], FGFR3 was higher in 
non-invasive (pTa) compared to invasive (pT2) tumors 
and was associated with low grade compared with 
high grade. Both COX-2 and FGFR-3 showed positive 
correlations to tumor grade (p = 0.020, p = 0.028), 
respectively. Further, multiple-response analytical 
statistics were performed, in which low-grade tumors 
that were positive to COX-2 and FGFR-3 showed a 
positive correlation (p = 0.028). This strongly suggests 
that both COX-2 and FGFR-3 show over-expression 
more commonly in lower grade urothelial tumors.
The tumor size in this study showed a positive 
correlation for FGR-3 staining (p = 0.028.) This may 
be attributed to many studies that postulate the link 
between FGFR-3 expression in lower grade tumors, 
with a smaller size and lower stage [15]. On the other 
hand, this study displayed no linear correlation between 
COX-2 expression and tumor size. Thus, these 
interesting results similarly supported by Hammam 
et al. [11], who argued that COX-2 may have more of a 
tumorigenic role rather than a prognostic impact.
From a histologic standpoint, invasive 
urothelial carcinoma was the predominant subtype in 
this study and accounted for 31% of all cases. There 
was no significant correlation seen regarding FGFR3 
(p = 0.121), similar to Tomlinson et al. [12], who also 
showed no significant association between FGFR3 
mutation status and histologic subtype (p = 0.106). 
Youssef et al. [18] showed a positive correlation of 
histologic type and COX-2 (p ≤ 0.005). This discrepancy 
may be due to a large amount of schistosomal cases 
(n = 205) in comparison to non-schistosomal cases 
(n = 110) in their study which is associated more 
commonly with squamous cell histologic variant.
In this study, concomitant in situ changes were 
evident in only 31 cases (34.3%). Showing a smaller 
percentage, Youssef et al. [18] demonstrated that 
only 29 cases (9.2%) showed associated carcinoma 
in situ. This may be due to a larger percentage of non-
papillary late-stage tumors in their study. Similarly, 
in our study, an insignificant correlation was seen 
between FGFR-3 and concomitant in situ changes; 
however, a positive statistic finding was seen when 
correlating COX-2 (p = 0.034). Jacobs et al. [20] 
additionally reported that 93% of CIS showed COX-2 
expression. Moreover, another study [19] reported 
that 86% of invasive transitional cell carcinomas, 78% 
of non-invasive transitional cell carcinomas, and 75% 
of CIS were COX-2 positive. In addition, in 53% of 
cases, morphologically normal epithelium adjacent to 
the cancer lesion was COX-2 positive. They reported 
that this indicates that morphologically normal epithelial 
cells may change into tumor cells due to a paracrine 
effect caused by increased cytokines and/or growth 
factors [19], [20].
Regarding metastatic tumor deposits to 
regional lymph nodes, a study performed in Egypt on 
315 cases of bladder cancer, showed a positive nodal 
metastasis of 30% and positive LVI emboli of 30.5%. 
However, in our study, a higher percentage (60%) of 
lymphatic invasion was seen [18]. Previous studies have 
reported that the rate of LVI ranges from 35% to 55% in 
muscle-invasive bladder carcinoma. Regarding COX-2, 
no statistical relationship was developed in this study 
between it and lymph node status nor LVI (p = 0.074, 
p = 0.018), respectively. On similar terms, a large 
study performed on 773 bladder cancer patients also 
showed no statistical relationship to COX-2 regarding 
lymph node status or invasion (p = 0.296, p = 0.869), 
respectively. Yamada et al. [23] observed positive 
findings between primary COX-2-positive patients and 
metastatic COX-2-positive patients (p = 0.03). This 
finding is significant since it suggests that metastatic 
lymph nodes are likely to be COX-2 positive when the 
primary tumor is COX-2 positive.
A significant correlation was also detected 
between FGFR3 expression and nodal status, in which 
FGFR3 expression was seen in 80% of the cases with 
positive regional lymph node metastasis (p ≤ 0.0006). 
In relation to LVI, another strong correlation was also 
established in this study (p = 0.0028). On the other 
hand, different findings were found in the study led by 
Baldia et al. [21], in which no significant finding was 
seen (p = 0.087). This may be due to the fact that the 
cohort study group was only squamous cell carcinoma 
patients and did not include other histologic variants.
A positive correlation was analyzed between 
tumor stage and FGFR3 (p = 0.031). Similar to 
our findings, Poyet et al. [15] showed a significant 
association between tumor stage and grade and 
FGFR3 immunoreactivity (both p < 0.001). Prognostic 
research involving the grade of bladder carcinomas 
explained that the overall survival was significantly 
better in patients with low-grade tumors compared to 
high-grade tumors (p = 0.011) and that patients with 
stage pTa had a significantly better overall survival than 
patients with invasive tumors [31].
The diagnosis of schistosomal bladder 
cancer was determined based on histological proof of 
bilharziasis (calcified eggs of S. haematobium) in the 
studied cases. Of the ninety cases, 32 cases (35.6%) 
showed bilharzial ova. Statistical analysis showed 
a positive correlation for both COX-2 and FGFR-3 
(p = 0.007, p = 0.015), respectively. Another study 
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El-Sheikh et al. [26] showed COX-2 overexpression 
was associated with pathological T stage (p = 0.01), 
grade p < 0.001), LVI (p = 0.041), and bilharziasis 
p = 0.045). Similar results supported that COX-2 
expression was significantly higher in schistosomal-
associated TCC than in non-schistosomal-associated 
TCC (p < 0.01).
In relation to FGFR3, Hammam et al. [11] 
showed that 54.5% of their study cases showed 
FGFR3 immunostaining and demonstrated a positive 
correlation of bilharzial bladder cancers and FGFR-3 
(p ≤ 0.001). Further Chi-square analytical studies were 
performed to show if a relation between COX2 and 
FGFR3 exists between the schistosomal-associated 
cases, in which positive correlation was established 
between the bilharzial-associated low-grade COX2 and 
FGFR3 cases (p = 0.025, p = 0.028), respectively.
Our second interpretation of the results goes 
in hand in hand with the fact that normal urothelial cells 
predominantly express high levels of cyclooxygenase 
(COX)-1, while bladder cancer cells show COX-2 
overexpression [26]. COX2 expression, according to 
these results, is higher, especially when associated with 
inflammatory conditions such as schistosomiasis which 
is predominant in Egypt. According to Kluth et al. [25], 
combining celecoxib with BCG for schistosomal-
associated cases was found to increase tumor 
infiltration of CD4+ T cells with a significant reduction 
of tumor burden. Thus, similar to the results of Yamada 
et al. [23], patients may benefit from treatment with 
selective COX-2 inhibitors in addition to the usual BCG 
treatment administered to the schistosomal cases in 
Egypt to limit progression of the tumor.
Conclusion
FGFR3 has been revealed to possess an 
oncogenic role in bladder cancer and mutations are 
found in up to 80% of primary low-grade tumors [24]. 
Our results have shown that FGFR3 expression is 
positive with low grade and low stage tumors and is 
statistically supported. Detection of FGFR3 mutations 
in urine should be employed for general population 
screening aimed at the early detection of primary 
tumors [22].
The results of this study established a positive 
correlation of FGFR3 in relation to tumor size, stage, 
grade, nodal status, and LVI. As for COX2, we have 
proven the significant findings in relation to grade, LVI 
and CIS. Schistosomiasis showed a clear cut correlation 
to both FGFR3 and COX2 in this study with a strong 
association to low-grade tumors and CIS areas.
Our recommendation is the consideration of 
FGFR-3 and selective COX-2 inhibitors for their use 
alone or in combination with conventional treatment 
such as intravesical BCG in cases associated with 
schistosomal infection.
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